GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Change in Director(s) of the company.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts more than Nifty Midcap 150 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
GSK Pharmaceuticals announced audited financial results for FY25 (year ended 31 March 2025). Standalone revenue from operations rose to Rs. 3,723 crore from Rs. 3,407 crore, up about 9.3% year-on-year. Standalone profit after tax jumped to Rs. 919 crore from Rs. 585 crore, a strong ~57% growth, helped by a low base (last year included a one-time Rs. 143 crore charge for a Voluntary Retirement Scheme) and higher other income. EPS after exceptional items rose to Rs. 54.24 from Rs. 34.51. The Board recommended a final dividend of Rs. 42 per share (up from Rs. 32 last year), with a record date of 30 May 2025. The 100th AGM is scheduled for 27 June 2025. Dr. Sunita Maheshwari was reappointed as Independent Director for a second 3-year term, and Parikh & Associates was appointed as Secretarial Auditor for 5 years (FY26–FY30). Statutory auditor Deloitte Haskins & Sells LLP issued an unmodified opinion.
Strong earnings beat driven by both revenue growth and margin expansion, paired with a ~31% dividend hike, signals robust shareholder returns and operational health. Expect positive short-term market reaction; the stock may also benefit from continued cash generation (operating cash flow more than doubled to Rs. 1,280 crore).